BC
SYRS

Bridgefront Capital’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Bridgefront Capital’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,054
Closed -$114K – 954
2020
Q4 		$114K Buy
+1,054
New +$96.2K 0.04% 561

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Bridgefront Capital's SYRS Position: Q1 2021 in Review

Bridgefront Capital sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2021, closing a stake of 1,054 shares — an estimated $114K sold.

Bridgefront Capital first reported a position in SYRS in Q4 2020 and held it in 1 quarter. The position peaked at $114K in Q4 2020. 106 funds tracked by Wall St. Rank hold SYRS as of Q1 2021.

  • Bridgefront Capital reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Bridgefront Capital sold 1,054 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2021, an estimated $114K.
  • Bridgefront Capital first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Bridgefront Capital's Syros Pharmaceuticals, Inc. Common Stock position peaked at $114K in Q4 2020.
  • 106 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2021.

Based on Bridgefront Capital's 13F filing for Q1 2021, filed 17 May 2021.